NCT06956092

Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

Prospective Clinical Study of Glofitamab for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma

• Status: Not Yet Recruiting
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 40 (estimated)
• Sponsor: Zhengzhou University · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

The goal of this clinical trial is to learn if Glofitamab works for consolidation after first-line treatment of high-risk Large B-cell Lymphoma (LBCL). It will also learn about the safety of Glofitamab treatment. The main questions it aims to answer are: * Does Glofitamab treatment result in prolonged clinical benefit to patients with high-risk LBCL after first-line treatment? * What medical problems do participants have when receiving Glofitamab treatment? In this investigator-initiated, single-arm clinical trial, participants will: * Receive Glofitamab treatment as per the instructions in the package insert. * Visit the clinic as instructed for checkups and tests.

Conditions

• B Cell Lymphoma (BCL)

Interventions

Type	Name	Description
BIOLOGICAL	Glofitamab treatment	eceive Glofitamab treatment as per the instructions in the package insert.

Timeline

• Start date: 2025-05-30
• Primary completion: 2028-06-01
• Completion: 2028-12-01
• First posted: 2025-05-02
• Last updated: 2025-05-02

Locations

1 site across 1 country: China